SWAV:NSD-ShockWave Medical Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 160.69

Change

-4.88 (-2.95)%

Market Cap

USD 5.73B

Volume

0.32M

Avg Analyst Target

USD 205.38 (+27.81%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ShockWave Medical Inc (SWAV) Stock Analysis:
Based on the ShockWave Medical Inc stock forecasts from 7 analysts, the average analyst target price for ShockWave Medical Inc is USD 205.38 over the next 12 months. ShockWave Medical Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of ShockWave Medical Inc is Slightly Bullish , which is based on 8 positive signals and 5 negative signals. At the last closing, ShockWave Medical Inc’s stock price was USD 160.69. ShockWave Medical Inc’s stock price has changed by -2.88% over the past week, -11.26% over the past month and -7.81% over the last year.

About

ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-24 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

-35.79 (-11.05%)

USD31.52B 164.23 78.28
ALGN Align Technology Inc

-8.53 (-3.06%)

USD21.96B 31.38 19.14
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
PODD Insulet Corporation

+14.98 (+7.38%)

USD13.78B 310.99 89.04
ABMD Abiomed Inc

-0.03 (-0.01%)

USD11.35B 83.63 39.39
BRKR Bruker Corporation

-0.95 (-1.57%)

USD8.99B 32.53 18.24
IART Integra LifeSciences Holdings ..

-0.59 (-0.97%)

USD4.98B 32.54 17.44
TNDM Tandem Diabetes Care Inc

-5.85 (-8.22%)

USD4.67B 820.11 190.18
IRTC iRhythm Technologies Inc

-8.42 (-6.06%)

USD3.96B N/A N/A
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67

ETFs Containing SWAV

Symbol Name Weight Mer Price(Change) Market Cap
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

-1.25 (-1.06%)

USD0.27B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.89% 86% B 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.89% 86% B 64% D
Trailing 12 Months  
Capital Gain -8.79% 88% B+ 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.79% 88% B+ 62% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 85.67% 86% B 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 85.67% 86% B 94% A
Risk Return Profile  
Volatility (Standard Deviation) 108.72% 24% F 12% F
Risk Adjusted Return 78.79% 93% A 92% A-
Market Capitalization 5.73B 95% A 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 196.35 20% F 7% F
Price/Book Ratio 21.70 8% F 4% F
Price / Cash Flow Ratio 381.39 2% F 1% F
EV/EBITDA 154.44 13% F 6% F
Management Effectiveness  
Return on Equity 12.28% 93% A 73% C
Return on Invested Capital -0.47% 68% D+ 50% F
Return on Assets 6.23% 91% A- 84% B
Debt to Equity Ratio 4.81% 78% C+ 80% B-
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.55 72% C- 57% F
Short Percent 3.27% 57% F 47% F
Beta 1.49 35% F 27% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.